

WHAT DOES THE BEAT-PKD CLINICAL TRIAL INVOLVE?

- 7 in-person clinic visits
- 5 outpatient lab visits
- 3 MRI scans
- 2 years of participation
- 1 daily pill (either BA or placebo)

WILL I BE PAID TO PARTICIPATE?

You will be paid \$100 for your time for each in-person research visit and \$25 for each lab visit. You will not be responsible for the costs of the study medication or study tests.

TO LEARN MORE:

<https://beat-pkdstudy.pitt.edu/>



CONTACT US:

University of Vermont Medical Center

Dr. Kenneth Hallows:
kenneth.hallows@uvmhealth.org
Kira Gotwals:
kira.gotwals@uvmhealth.org

University of Maryland, Baltimore


Dr. Stephen Seliger:
sseliger@som.umaryland.edu
Charalett Diggs:
charalett.diggs@som.umaryland.edu

Tufts Medical Center, Boston

Dr. Dana Miskulin:
dana.miskulin@tuftsmedicine.org
Shuaib Mohammed:
shuaib.mohammed@tuftsmedicine.org

*Funded by the U.S. Department of Defense
ClinicalTrials.gov ID: NCT07282821
Approved by University of Maryland, Baltimore
IRB HP-00114205*

BEAT-PKD CLINICAL TRIAL



University of Vermont Medical Center
1 S Prospect St., Burlington, VT 05401

University of Maryland, Baltimore
685 W. Baltimore St., Howard Hall #304,
Baltimore, MD 21201

Tufts Medical Center, Boston
800 Washington St., Boston, MA 02111

WHAT IS THE BEAT-PKD CLINICAL TRIAL?

BEAT-PKD stands for Bempedoic Acid Therapy for Polycystic Kidney Disease.

WHY IS THE BEAT-PKD CLINICAL TRIAL BEING DONE?

This clinical trial will investigate whether Bempedoic Acid is safe and tolerable in adults with ADPKD who are at high risk of worsening disease, whether or not you are already taking tolvaptan.

WHAT IS BEMPEDOIC ACID?

Bempedoic Acid or BA is an FDA approved medicine that lowers cholesterol levels and it is thought to potentially improve ADPKD. It is not approved by the FDA to treat ADPKD.

WHY IS BEMPEDOIC ACID IN A KIDNEY STUDY?

Use of this medicine in mouse models by the physicians leading this study has shown that Bempedoic Acid can slow the enlargement of kidneys and the decline of kidney function in ADPKD. The results can be viewed in the 2022 paper listed below:

Beneficial effects of bempedoic acid treatment in polycystic kidney disease cells and mice. Front. Mol. Biosci. 9:1001941. doi: 10.3389/fmolb.2022.1001941

WHO ARE THE PARTICIPATING SITES?

- University of Vermont Medical Center
- University of Maryland, Baltimore
- Tufts Medical Center, Boston

AM I ELIGIBLE TO PARTICIPATE?

- Have Autosomal Dominant Polycystic Kidney Disease
- Be between the ages of 18-60
- Have a Mayo Imaging Classification of 1C-1E, or 1B with worsening kidney function
- Be fluent English-speaking
- Not have recurrent gout or abnormal liver function
- If on tolvaptan, must be on the same dose for at least 3 months

